

chain nodes :

7 8 9 18 20 22 23 24 31 32 33 34 35 36

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15 25 26 27 28 29 30

chain bonds :

5-7 7-8 8-9 8-18 9-12 20-22 20-23 23-31 24-27 24-33 31-32 32-33
32-34 34-35 34-36

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
25-26 25-30 26-27 27-28 28-29 29-30

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 8-18 20-22 20-23 24-33 32-33
34-35 34-36

exact bonds :

8-9 9-12 23-31 24-27 31-32 32-34

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15 25-26 25-30 26-27 27-28 28-29
29-30

isolated ring systems :

containing 1 :


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS

10/031,121

=>

Uploading C:\Program Files\Stnexp\Queries\10031121.str



chain nodes :

7 8 9 18 20 22 23 24

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15 25 26 27 28 29 30

chain bonds :

5-7 7-8 8-9 8-18 9-12 20-22 20-23 23-24 24-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15 25-26
25-30 26-27 27-28 28-29 29-30

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 8-18 20-22 20-23 23-24

exact bonds :

8-9 9-12 24-27

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15 25-26 25-30 26-27 27-28 28-29 29-30

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:32:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS


10/031,121

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10031121 (a).str



chain nodes :

7 8 9 18 20 22 23 24 31 32 33 34 35 36

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15 25 26 27 28 29 30

chain bonds :

5-7 7-8 8-9 8-18 9-12 20-22 20-23 23-31 24-27 24-33 31-32 32-33 32-34
34-35 34-36

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15 25-26
25-30 26-27 27-28 28-29 29-30

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 8-18 20-22 20-23 24-33 32-33 34-35
34-36

exact bonds :

8-9 9-12 23-31 24-27 31-32 32-34

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15 25-26 25-30 26-27 27-28 28-29 29-30

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 16:34:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L3

=> s 13 sss ful

FULL SEARCH INITIATED 16:35:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS

40 ANSWERS

SEARCH TIME: 00.00.01

L5 40 SEA SSS FUL L3

=> => s 15

L6 2 L5

=> d 16 1-2 bib,ab,hitstr

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:62380 CAPLUS
 DN 134:115966
 TI Preparation of 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
 IN Breipohl, Gerhard; Peyman, Anuschirwan; Wollmann, Theodor
 PA Aventis Pharma Deutschland G.m.b.H., Germany
 SO Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1070707	A1	20010124	EP 1999-114372	19990721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	WO 2001007417	A1	20010201	WO 2000-EP6504	20000708
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012554	A	20020416	BR 2000-12554	20000708
	TR 200200116	T2	20020422	TR 2002-200200116	20000708
	EP 1204646	A1	20020515	EP 2000-956171	20000708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003505450	T2	20030212	JP 2001-512503	20000708
	EE 200200031	A	20030217	EE 2002-31	20000708
	NZ 516233	A	20040730	NZ 2000-516233	20000708
	AU 775567	B2	20040805	AU 2000-68226	20000708
	ZA 2001010361	A	20021218	ZA 2001-10361	20011218
	BG 106322	A	20020830	BG 2002-106322	20020118
	NO 2002000311	A	20020121	NO 2002-311	20020121
	HR 2002000057	A1	20030630	HR 2002-57	20020121
PRAI	EP 1999-114372	A	19990721		
	WO 2000-EP6504	W	20000708		

OS MARPAT 134:115966

AB Et (2S)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate was prepared by reacting 4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoic acid (or a derivative) with Et (2S)-3-amino-2-(naphthalene-1-sulfonylamino)propionate. The compound can be used, for example, in the treatment or prophylaxis of diseases which can be influenced by inhibiting the vitronectin receptor, in particular of bone diseases such as osteoporosis.


IT **232918-36-4P 321522-99-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrahydropyrimidine derivative as a vitronectin inhibitor)

RN 232918-36-4 CAPLUS

CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321522-99-0 CAPLUS


CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, ethyl ester, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 232918-36-4

CMF C29 H33 N5 O6 S

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

10/031,121

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:487276 CAPLUS

DN 131:116254

TI Preparation of arylsulfonamides as vitronectin receptor antagonists

IN Peyman, Anuschirwan; Will, David William; Knolle, Jochen; Scheunemann, Karlheinz; Carniato, Denis; Gourvest, Jean-Francois; Gadek, Thomas; Mcdowell, Robert; Bodary, Sarah Catherine; Cuthbertson, Robert Andrew

PA Hoechst Marion Roussel Deutschland G.m.b.H., Germany; Genentech, Inc.

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937621	A1	19990729	WO 1999-EP242	19990116
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2318221	AA	19990729	CA 1999-2318221	19990116
	AU 9925181	A1	19990809	AU 1999-25181	19990116
	AU 752882	B2	20021003		
	BR 9907735	A	20001017	BR 1999-7735	19990116
	EP 1049677	A1	20001108	EP 1999-904789	19990116
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	TR 200002160	T2	20010723	TR 2000-200002160	19990116
	JP 2002501054	T2	20020115	JP 2000-528545	19990116
	NZ 505613	A	20021126	NZ 1999-505613	19990116
	ZA 9900476	A	19990805	ZA 1999-476	19990122
	US 6313119	B1	20011106	US 2000-564988	20000505
	NO 2000003765	A	20000925	NO 2000-3765	20000721
	BG 104630	A	20010430	BG 2000-104630	20000721
	HR 2000000493	A1	20010630	HR 2000-493	20000721
	US 2002065271	A1	20020530	US 2001-972190	20011009
	US 6747148	B2	20040608		
PRAI	US 1998-12489	A	19980123		
	US 1998-72313P	P	19980123		
	WO 1999-EP242	W	19990116		
	US 1999-235271	B1	19990122		
	US 2000-564988	A3	20000505		

OS MARPAT 131:116254

AB R5SO2NHCH(CO2R4)CH2NHCOZCH2CH2CONHC(:NR1)NR2R6 [I; R1,R2 = H or (un)substituted alkyl; R1R2 = atoms to complete a ring; R4 = H, (un)substituted alkyl, etc.; R5 = alkyl, (hetero)aryl(alkyl); R6 = H, OH, alkoxy carbonyl, etc.; Z = 1,4-phenylene] were prepared. Thus, (S)-H2NCH2CH(NHCO2CH2Ph)CO2CMe3 was amidated by 4-(MeO2C)C6H4CO2H (preparation given) and the deprotected product N-sulfonated by 1-naphthalenesulfonyl chloride to give the diester which was amidated by 2-amino-1,4,5,6-tetrahydropyrimidine to give, after saponification, title compound (S)-II.

Data for

biol. activity of I were given.


IT 232918-07-9P 232918-08-0P 232918-09-1P
 232918-10-4P 232918-11-5P 232918-14-8P
 232918-16-0P 232918-17-1P 232918-19-3P
 232918-20-6P 232918-21-7P 232918-22-8P
 232918-23-9P 232918-25-1P 232918-26-2P
 232918-27-3P 232918-28-4P 232918-34-2P
 232918-35-3P 232918-36-4P 232918-37-5P
 232918-38-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylsulfonamides as vitronectin receptor antagonists)

RN 232918-07-9 CAPLUS

CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-08-0 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-(8-quinolinylsulfonyl)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-09-1 CAPLUS

CN L-Alanine, N-[[4-(acetamido)phenyl]sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-10-4 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[[2-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-11-5 CAPLUS

CN L-Alanine, N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-14-8 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[(4-propylphenyl)sulfonyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-16-0 CAPLUS

CN L-Alanine, N-[(4-butoxyphenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-17-1 CAPLUS

CN L-Alanine, N-[(2-cyanophenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-19-3 CAPLUS

CN L-Alanine, N-[(4-chlorophenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-20-6 CAPLUS

CN L-Alanine, N-[(3-chlorophenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-21-7 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-22-8 CAPLUS

CN L-Alanine, N-[(4-methoxyphenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-23-9 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-25-1 CAPLUS

CN L-Alanine, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 232918-26-2 CAPLUS

10/031,121

CN L-Alanine, N-(2-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-27-3 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-28-4 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-34-2 CAPLUS

CN L-Alanine, N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-35-3 CAPLUS

CN L-Alanine, N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-36-4 CAPLUS

CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-37-5 CAPLUS

CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-38-6 CAPLUS

CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 2-methylpropyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 232918-42-2P 232918-44-4P 232918-46-6P
232918-48-8P 232918-50-2P 232918-56-8P
232918-60-4P 232918-62-6P 232918-66-0P
232918-68-2P 232918-70-6P 232918-72-8P
232918-74-0P 232918-78-4P 232918-80-8P
232918-82-0P 232918-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of arylsulfonamides as vitronectin receptor antagonists)

RN 232918-42-2 CAPLUS

CN L-Alanine, N-(1-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 232918-44-4 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-(8-quinolinylsulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-46-6 CAPLUS

CN L-Alanine, N-[[4-(acetamido)phenyl]sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-48-8 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[[2-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-50-2 CAPLUS

CN L-Alanine, N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-56-8 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[(4-propylphenyl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-60-4 CAPLUS

CN L-Alanine, N-[(4-butoxyphenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-62-6 CAPLUS

CN L-Alanine, N-[(2-cyanophenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 232918-66-0 CAPLUS

CN L-Alanine, N-[(4-chlorophenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-68-2 CAPLUS

CN L-Alanine, N-[(3-chlorophenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-70-6 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[[3-(trifluoromethyl)phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-72-8 CAPLUS

CN L-Alanine, N-[(4-methoxyphenyl)sulfonyl]-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-74-0 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-(phenylsulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-78-4 CAPLUS

CN L-Alanine, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-80-8 CAPLUS

CN L-Alanine, N-(2-naphthalenylsulfonyl)-3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-82-0 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[(2,4,6-trimethylphenyl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 232918-84-2 CAPLUS

CN L-Alanine, 3-[[4-[3-oxo-3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]benzoyl]amino]-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/031,121

=> => d his

(FILE 'HOME' ENTERED AT 16:32:07 ON 01 OCT 2004)

FILE 'REGISTRY' ENTERED AT 16:32:14 ON 01 OCT 2004

L1	STRUCTURE UPLOADED
L2	0 S L1 SSS SAM
L3	STRUCTURE UPLOADED
L4	2 S L3 SSS SAM
L5	40 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 16:35:21 ON 01 OCT 2004

L6	2 S L5
----	--------

FILE 'CAOLD' ENTERED AT 16:35:50 ON 01 OCT 2004

=> s l5

L7	0 L5
----	------

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	167.69

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.40

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:36:17 ON 01 OCT 2004